Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Major Pharma Companies

Immunological and Autoimmune Disorders

FcRn Inhibitors for Autoimmune Disorders: A Pro...

Autoimmune disorders, a group of conditions where the immune system mistakenly attacks healthy cells, affect millions worldwide, often leading to debilitating symptoms and reduced quality of life. ...

May 06, 2024

Pharma News for BeiGene, GSK, Sandoz, Travere
BeiGene’s BRUKINSA Gets FDA Accelerated Approval; GSK’s Positive Results in DREAMM-8 Phase III; Sandoz’s Denosumab Biosimilars FDA Approved; Terns Pharma’s TERN-701 Receives Orphan Drug Designation; Wegovy® Approved in US for Overweight Cardiovascular Risk; Travere Therapeutics Submits sNDA for FILSPARI IgAN Full Approval

BeiGene Receives FDA Accelerated Approval for BRUKINSA in Relapsed/Refractory Follicular Lymphoma BeiGene, Ltd., has declared that the FDA has provided accelerated approval for BRUKINSA® (zanubrutinib) to be used in treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), when used alo...

Find More
AAAAI Annual Meeting Highlights
Major Highlights and Insights from the AAAAI Annual Meeting, 2024

American Academy of Allergy, Asthma & Immunology (AAAAI) 2024 annual meeting, is the premier educational event for allergists/immunologists around the world that was held from February 23 to 26 at the Walter E. Washington Convention Center this year. The American Academy of Allergy, Asthma & Immunology (AAA...

Find More
Pharma News for Bayer, AstraZeneca, AbbVie, A2 Bio
Bayer’s New Cardiology Drug Acoramidis; Two Datopotamab Deruxtecan Applications Validated in the EU; AbbVie and OSE Immunotherapeutics Announce Announces Partnership; vTv Therapeutics Makes Major Move With Cadisegliatin; A2 Bio Scores FDA Orphan Drug Designation for its Therapy, A2B530; FDA Fast Track Designation for AlloNK® in Lupus Nephritis

Acoramidis Joins Bayer's Robust Lineup, Boosting Cardiology Solutions Bayer has obtained the exclusive rights to market acoramidis in Europe from Eidos Therapeutics Inc., BridgeBio International GmbH, and BridgeBio Europe B.V. Acoramidis, a highly potent and selective small molecule given orally, functions as a ...

Find More

More Views & Analysis

xolair-for-food-allergy-treatment
Revolutionizing the Food Allergy Treatment: The Impact of Xolair’s Approval

Individuals suffering from food allergies now have access to a medication that can potentially avert serious consequences. This medication, which has been available for twenty years, has received approval from the FDA. Xolair (omalizumab) by Roche and Novartis is the first food allergy treatment sanctioned to dimin...

Find More

Pharma News for GSK, Sanofi, Biogen, Artiva
Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease; GSK Announces Positive Headline Results from EAGLE-1 Phase III Trial; Dupixent sBLA Accepted for FDA Priority Review; Biogen’s QALSODY Received Positive Opinion from CHMP; FDA Granted Orphan Drug Designation to Immune-Onc’s IO-202; Artiva Biotherapeutics’s AlloNK® in Lupus Nephritis

Survodutide Phase II trial Shows Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis Boehringer Ingelheim has reported that in a Phase II trial, a significant proportion of adults treated with survodutide (BI 456906), up to 83.0%, showed a notable enhancement in metabol...

Find More

Pharma News for Novartis, Iovance, Certa, Innovent
FDA Approves Xolair for Food Allergies; FDA Accelerated Approval for Iovance’s AMTAGVI; Astellas and Kelonia Enter into Research and License Agreement; Fast Track Designation to Certa’s FT011; Innovent Announces Phase 3 Clinical Trial Updates for IBI311; Orphan Drug Designation to Cardiol’s Pericarditis Drug Candidate

FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies Roche has announced that the FDA has approved Xolair® (omalizumab) to mitigate allergic responses, such as anaphylaxis, that may arise from accidental exposure to various foods in both adult and pediatric patie...

Find More

Pressure Relief Devices Market Analysis
Pressure Relief Devices: Charting the Course of Market Evolution and Major Developments

Pressure relief devices have undergone a remarkable evolution over the years, catering to the diverse needs of individuals for enhanced comfort and medical support. Initially simple in design, these devices have evolved into sophisticated solutions that address specific medical conditions and promote overall well-b...

Find More

Navigating the Healthcare Horizon: Odyssey of Mergers, Funding, and Acquisitions in 2024

As we step into the crisp corridors of 2024, the healthcare landscape unfolds a compelling saga of mergers, strategic funding, and transformative acquisitions. In this month-by-month analysis, we delve into the intricate tapestry of industry dynamics, exploring the impactful maneuvers that are shaping the healthcar...

Find More

Pharma News For Astellas, AnaMar, Biosyngen
4DMT Presents Data From Phase II PRISM Clinical Trial; Adaptimmune Announces FDA Acceptance of Biologics License Application for Afami-cel; Astellas Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA; AnaMar Announces US and EU Orphan Drug Designation for AM1476; Biosyngen Announces FDA Fast Track Designation for BST02; Acepodia Announces FDA Clearance of IND Application for ACE2016

4DMT Presents Positive Interim Data from Randomized Phase II PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD 4D Molecular Therapeutics, a prominent company in the field of genetic medicines with a focus on harnessing the full potential of geneti...

Find More

Ankylosing spondylitis (AS) is an inflammatory disease that results in a progressive fusion of some .....

Find More

Neurofibromatosis is a progressive and autosomal dominant inherited disorder of the nervous system w.....

Find More

Past decades have witnessed a shift in the focus of researchers and pharma companies towards tailori.....

Find More

A complex genetic condition, Prader-Willi syndrome (PWS) is a result of the loss of the functioning .....

Find More

Digital therapies are evidence-based clinical approaches powered by software applications designed t.....

Find More

Herpes zoster oticus (HZ oticus) is a viral infection of the inner, middle, and external ear. A resu.....

Find More